# Inspecting products and practices

Consulter la version française

In its health authority capacity, ANSM, through its inspection activity, monitors the quality of practices among operators (manufacturers, operators, importers, distributors, trial sponsors, investigators, etc.), as well as the quality and safety of healthcare products, including starting materials.

As such, ANSM :

- helps to define enforceable regulatory frameworks (especially good practices and applicable standards);
- manages the corresponding sites (authorisations, accreditations, declarations, sanctions, etc.);
- ensures that the enforceable regulatory provisions are implemented, via on-site inspections in the context of an annual or random inspection programme.

**The ANSM Inspection Division is accredited by COFRAC (French Accreditation Committee) in accordance with the ISO/IEC 17020 standard**. This accreditation constitutes recognition of the quality of ANSM's inspection activities, as well as their compliance with ethics and international regulations related to impartiality, independence, and competence.

+ Find out more about ANSM's COFRAC accreditation

## Managing sites

### For medicines and starting materials

To open a pharmaceutical site, operators conducting activities related to the marketing of medicines in France or Europe are subject to ANSM's prior authorisation scheme.

Similarly, sites that manufacture, import, and distribute active substances are subject to ANSM's authorisation scheme. Sites that perform these same activities for excipients are subject to a report-based scheme.

+ Find out more about the authorisation to open a pharmaceutical site
+ Go to the MPUP electronic reporting portal

### For labile blood products and other biological products

Labile blood products are obtained from blood donations. They include cell products and plasmas and are intended to be transfused to patients. Sites carrying out transfusion activities are accredited to do so via a decision by ANSM's Director General.

All activities pertaining to the preparation, storage, distribution, sale/transfer, import or export of tissues, their derivatives, cells and cell therapy preparations, of human origin, used for therapeutic purposes are subject to prior authorisation by ANSM's Director General.

In order to carry out any activity pertaining to the preparation, storage, distribution, or sale/transfer of innovative therapy medicines prepared on a one-off basis (including experimental medicines), prior authorisation from ANSM's Director General is also required.

For breast milk banks, ANSM oversees the technical appraisal of operating authorisation applications, which are issued by regional health agencies (ARS).

Similarly, the storage, use, inter-site transfer, import and export of certain agents responsible for infectious diseases, pathogenic microorganisms and toxins (MOT) require authorisation from ANSM. Authorisations are granted once the biological safety and security risks have been assessed. ANSM also monitors licensed representatives who are authorised to store and handle MOTs, and collects administrative reports and notifications of any events that could potentially result in the spread of MOTs.

+ Report information for Microorganism and toxins

+ Apply for authorisation for Microorganism and toxins

## For medical devices (MDs) and in vitro diagnostic medical devices (IVDMDs)

To open their site, operators releasing MDs or IVDMDs to the French or European market do not require prior authorisation.

However, ANSM oversees device post-marketing surveillance, particularly through inspections in order to ensure compliance with the requisite essential requirements and the conformity of the devices on the market.

## Inspecting sites

Inspections make it possible to establish a degree of confidence in the quality of the practices of the players involved (manufacturers, operators, importers, distributors, trial sponsors, investigators, etc.), who remain primarily responsible for their practices, the quality and safety of the health products and the safety of patients included in trials and, more generally, the use of health products in human health.

The purpose of these inspections is to :

- assess the compliance of the practices of the players involved (manufacturers, healthcare institutions, clinicians, etc.) with the best practices or standards in force for an activity, product, or clinical or non-clinical trials, with a view to ensuring that they are capable of producing quality data and/or health products safely;
- carry out technical investigations in response to a report of a quality defect, incident, or especially a significant event (e.g. whistleblower intervention);
- gather the necessary information for subsequent administrative proceedings:
  - preparation of a technical opinion within the scope of the appraisal of applications for site authorisation or accreditation or marketing authorisation for medicines, tissues, and cell therapy preparations ;
  - issuance, renewal or withdrawal of a certificate (good manufacturing, distribution practice, etc.).

List of accredited and certified inspectors (18/12/2023)

### International inspection coordination

With a view to addressing the challenges associated with the globalisation of the medicine production, manufacturing and distribution chain, inspection activities are organised and harmonised on European and international levels. The harmonisation of practices, sharing of information of common interest and pooling of inspection resources have been organised by the competent authorities.

In this way, inspections are conducted worldwide according to the same high standards regardless of the manufacturing location, in the aim of improving access to safe and effective high-quality medicines. Inspections conducted by a Member State of the European Union are based on the principle of mutual recognition of inspections conducted on national territory and European Union-third countries. Mutual recognition agreements have also been signed with different countries allowing the recognition of inspections conducted on national territory.

## Inspection follow-up actions

Inspections may lead to the following administrative follow-up actions :

- Injunctions
- Health policy decisions

- Suspension of the activity at the source of the risk (suspension, withdrawal of authorisation or accreditation, etc.)
- Financial sanction

+ Find out more about inspection follow-up actions and administrative measures

The inspection may trigger criminal and disciplinary penalties.

Inspections are carried out in the context of an annual programme prepared based on risk mapping, particularly according to the nature of the activities carried out by the operators, according to previous inspection history, etc. Inspections can also be carried out following an internal referral or external request, particularly following a safety report received by ANSM. The operator may be notified of the inspections, or the inspections may be conducted on a spot-check basis. The Inspection Division allocates 10% of its inspection programme to inspections in third countries.

## Inspection report

An inspection is always finalised with an inspection report stating the deviations observed from the references. The inspection report is drafted using a jointly undertaken process involving sending a preliminary report to the operator. The operator may then disclose its responses, preventive or corrective actions to resolve the deviations observed. Based on these responses, the final report is drafted and is used to pronounce site compliance or take appropriate decisions in the event of non-compliance.

+ View inspection campaign summaries

## Different inspections

### Inspection of non-clinical trials

**Operators concerned**

Research facilities responsible for preclinical trials on:

- medicines for human use,
- medical devices (inspections on referral or after voluntary request from the trial facilities).

**Main frames of reference**

- French Public Health Code
- Good Laboratory Practice (GLP)

### Inspection of clinical trials

**Operators concerned**

- sites where clinical trials are carried out
- sponsors of these studies
- subcontractors (CROs)

**Main frames of reference**

- French Public Health Code
- Good Clinical Practice

### Inspection of pharmacovigilance activities

**Operators concerned**

- pharmaceutical sites
- service providers

**Main frames of reference**

- French Public Health Code
- Good Pharmacovigilance Practice

## Inspection of medical device vigilance activities

**Operators concerned**

- manufacturers
- agents
- importers
- distributors

**Main frames of reference**

- French Public Health Code

## Inspection of breast milk banks

**Operators concerned**

- breast milk banks

**Main frames of reference**

- French Public Health Code
- Good Breast Milk Bank Practice

## Inspection of microorganism and toxin (MOT) sites and authorisation holders

**Operators concerned**

- MOT authorisation holders
- sites carrying out activities on MOTs

**Main frames of reference**

- French Public Health Code
- Best practices aimed at ensuring biological safety and security

## Inspection of medicinal products and their starting materials

**Operators concerned**

- pharmaceutical sites
- operators that manufacture, import, and distribute active substances or excipients

**Main frames of reference**

- French Public Health Code

- Good Manufacturing Practice (GMP)
- Good wholesale Distribution Practice (GDP)
- Good Distribution Practice of active substances for human use
- Good Pharmacovigilance Practice
- Pharmacopoeia

## Inspection of blood products

**Operators concerned**

- blood transfusion centers

**Main frames of reference**

- French Public Health Code
- Good Transfusion Practice

## Inspection of tissues and cells of human origin

**Operators concerned**

- cell therapy units
- tissue banks

**Main frames of reference**

- French Public Health Code
- Good Tissue & Cell Practice

## Inspection of innovative therapy medicines (MTI) and innovative therapy medicines prepared on a one-off basis (MTI PP)

**Operators concerned**

- pharmaceutical sites
- operators authorised to manufacture MTI PP medicines

**Main frames of reference**

- French Public Health Code
- Good Manufacturing Practice specific to innovative therapy medicines

## Inspection of medical devices and in vitro diagnostic medical devices

**Operators concerned**

- notified bodies
- manufacturers
- agents
- distributors

**Main frames of reference**

- French Public Health Code
- Essential requirements

Download the guidelines of follow-up actions after an inspection (French version) (17/10/2017)

Download the guidelines of follow-up actions after an inspection (bilingual version) (14/05/2018)